Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. Financials
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
285.76 USD   +0.87%
12/07Amgen : When It Comes to Biosimilar Manufacturing, Heritage and Expertise Matter
PU
12/07Amgen : Investor Presentation December 2022
PU
12/07Amgen : Alliances Help Connect Patients with Lung Cancer to Precision Medicine Treatments
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 143 240133 852126 718152 476--
Enterprise Value (EV)1 164 232156 191151 990178 854176 721174 381
P/E ratio 18,7x18,7x21,9x23,6x19,2x17,7x
Yield 2,41%2,78%3,13%2,71%2,92%3,19%
Capitalization / Revenue 6,13x5,26x4,88x5,81x5,61x5,38x
EV / Revenue 7,03x6,14x5,85x6,82x6,51x6,15x
EV / EBITDA 12,3x9,80x9,61x11,2x10,9x10,3x
Price to Book 14,7x14,1x18,7x46,2x38,7x33,0x
Nbr of stocks (in thousands) 594 184582 169563 266533 579--
Reference price (USD) 241230225286286286
Announcement Date 01/30/202002/02/202102/07/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 23 36225 42425 97926 24127 16428 339
EBITDA1 13 36315 93515 82215 90216 18016 943
Operating profit (EBIT)1 11 15712 33412 42412 71412 89113 623
Operating Margin 47,8%48,5%47,8%48,5%47,5%48,1%
Pre-Tax Profit (EBT)1 9 1388 1336 7017 4708 9889 692
Net income1 7 8427 2645 8936 5097 7498 292
Net margin 33,6%28,6%22,7%24,8%28,5%29,3%
EPS2 12,912,310,312,114,916,2
Dividend per Share2 5,806,407,047,758,339,11
Announcement Date 01/30/202002/02/202102/07/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 6 2386 5946 6526 7596 4606 800
EBITDA1 3 9814 1634 1143 6894 1404 181
Operating profit (EBIT)1 3 1403 3353 2772 9533 1443 269
Operating Margin 50,3%50,6%49,3%43,7%48,7%48,1%
Pre-Tax Profit (EBT)1 1 6751 5312 3921 8842 5292 615
Net income1 1 4761 3172 1431 6132 1072 198
Net margin 23,7%20,0%32,2%23,9%32,6%32,3%
EPS2 2,682,453,983,063,934,12
Dividend per Share ------
Announcement Date 04/27/202208/04/202211/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 20 99222 33925 27226 37924 24521 905
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,57x1,40x1,60x1,66x1,50x1,29x
Free Cash Flow1 8 5329 8898 3819 04210 34110 994
ROE (Net Profit / Equities) 81,4%103%122%189%330%402%
Shareholders' equity1 9 6307 0764 8453 4442 3482 064
ROA (Net Profit / Asset) 14,3%16,0%15,8%10,8%12,3%14,1%
Assets1 54 77845 48137 32860 27063 00058 810
Book Value Per Share2 16,416,312,06,197,398,66
Cash Flow per Share2 15,017,816,218,619,821,3
Capex1 618608880875849871
Capex / Sales 2,65%2,39%3,39%3,33%3,12%3,08%
Announcement Date 01/30/202002/02/202102/07/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
J&J sues Amgen over plan to sell ulcerative colitis drug similar to Stelara
Key data
Capitalization (USD) 152 475 593 906
Net sales (USD) 25 979 000 000
Number of employees 24 200
Sales / Employee (USD) 1 073 512
Free-Float 99,8%
Free-Float capitalization (USD) 152 159 899 403
Avg. Exchange 20 sessions (USD) 921 945 916
Average Daily Capital Traded 0,60%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA